Cargando…

Mechanisms of contact sensitization offer insights into the role of barrier defects versus intrinsic immune abnormalities as drivers of atopic dermatitis

Detalles Bibliográficos
Autores principales:	Dhingra, Nikhil, Gulati, Nicholas, Guttman-Yassky, Emma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3773606/ https://www.ncbi.nlm.nih.gov/pubmed/24030647 http://dx.doi.org/10.1038/jid.2013.239

Ejemplares similares

A possible role for IL-17A in establishing Th2 inflammation in murine models of atopic dermatitis
por: Dhingra, Nikhil, et al.
Publicado: (2014)

Successful use of ustekinumab therapy in refractory severe atopic dermatitis
por: Shroff, Anjali, et al.
Publicado: (2014)

Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics
por: Mansouri, Yasaman, et al.
Publicado: (2015)

The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment
por: Facheris, Paola, et al.
Publicado: (2023)

Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches
por: Moyle, Matthew, et al.
Publicado: (2019)

Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis
por: Yang, Gabsik, et al.
Publicado: (2020)

Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
por: Gelato, Federica, et al.
Publicado: (2023)

Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention
por: Simpson, Eric L., et al.
Publicado: (2014)

Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Epidermal Permeability Barrier Defects and Barrier Repair Therapy in Atopic Dermatitis
por: Lee, Hae-Jin, et al.
Publicado: (2014)

Impact of vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the atopic dermatitis serum proteome
por: Kim, Madeline, et al.
Publicado: (2023)

Allergic contact dermatitis masquerading as atopic dermatitis
por: Semaan, Sarah, et al.
Publicado: (2020)

Tape-Strip Proteomic Profiling of Atopic Dermatitis on Dupilumab Identifies Minimally Invasive Biomarkers
por: He, Helen, et al.
Publicado: (2020)

Barrier defect in atopic dermatitis – possibilities and limits of basic skin therapy
por: Roesner, Lennart M., et al.
Publicado: (2021)

Epidermal Barrier in Atopic Dermatitis
por: Kim, Byung Eui, et al.
Publicado: (2012)

Changes in Skin and Nasal Microbiome and Staphylococcal Species Following Treatment of Atopic Dermatitis with Dupilumab
por: Olesen, Caroline Meyer, et al.
Publicado: (2021)

Priority research questions in atopic dermatitis: an International Eczema Council eDelphi consensus
por: Abuabara, K., et al.
Publicado: (2021)

Moderate-to-severe atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity
por: Vekaria, Anjali S., et al.
Publicado: (2017)

Prevalence of Atopic Dermatitis Criteria among Textile Workers with Occupational Allergic Contact Dermatitis and Effects of Having Atopic Dermatitis on Contact Antigenic Diversity
por: Taş, Betül, et al.
Publicado: (2019)

Epidermal barrier defects link atopic dermatitis with altered skin cancer susceptibility
por: Cipolat, Sara, et al.
Publicado: (2014)

Skin barrier defects in atopic dermatitis: From old idea to new opportunity
por: Yoshida, Takeshi, et al.
Publicado: (2022)

The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins
por: Brunner, Patrick M., et al.
Publicado: (2017)

339 Sensitization to Contactants in Patients with Atopic Dermatitis
por: Matsumoto, Fausto, et al.
Publicado: (2012)

Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records Dataset
por: Eichenfield, Lawrence F., et al.
Publicado: (2022)

Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate‐to‐severe disease
por: Sims, Jonathan T., et al.
Publicado: (2021)

Qualitative Assessment of Adult Patients’ Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional Study
por: Falissard, Bruno, et al.
Publicado: (2020)

Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
por: Bansal, Ashish, et al.
Publicado: (2021)

COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab
por: Ungar, Benjamin, et al.
Publicado: (2022)

Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement
por: Drucker, A.M., et al.
Publicado: (2018)

Author Correction: The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins
por: Brunner, Patrick M., et al.
Publicado: (2018)

ΔNp63 regulates IL-33 and IL-31 signaling in atopic dermatitis
por: Rizzo, J M, et al.
Publicado: (2016)

The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis
por: Ungar, Benjamin, et al.
Publicado: (2022)

Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways
por: Ewald, David A., et al.
Publicado: (2015)

Barrier function and microbiotic dysbiosis in atopic dermatitis
por: Seite, Sophie, et al.
Publicado: (2015)

Skin barrier in atopic dermatitis: beyond filaggrin
por: Zaniboni, Mariana Colombini, et al.
Publicado: (2016)

Significance of Skin Barrier Dysfunction in Atopic Dermatitis
por: Kim, Byung Eui, et al.
Publicado: (2018)

The Pathogenic and Therapeutic Implications of Ceramide Abnormalities in Atopic Dermatitis
por: Fujii, Masanori
Publicado: (2021)

Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial
por: Guttman-Yassky, Emma, et al.
Publicado: (2020)

Protocol for a prospective, observational, longitudinal study in paediatric patients with moderate-to-severe atopic dermatitis (PEDISTAD): study objectives, design and methodology
por: Paller, Amy S, et al.
Publicado: (2020)

Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey‐based position statement
por: Leshem, Y.A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_uapfkr4u3gc0oea7qi6veqhi7o